Primary aldosteronism (PA) is one the single most common causes of hypertension, but identifying patients with PA—and knowing which ones may benefit from a surgical treatment—can be quite challenging.

The list represents a collaboration between more than 30 nutritionists, doctors and epidemiologists. 

Former U.S. Surgeon General Jerome Adams spoke at the AHA 2022 Scientific Sessions and asked cardiologists to help end the COVID pandemic and tackle the even bigger epidemic of hypertension.

The SPYRAL HTN-ON MED renal denervation trial failed to show that renal denervation was superior to sham control at improving ambulatory blood pressure (ABPM), but that might have been due to patient lifestyle changes during COVID-19.

The more a patient has to pay for medications, the less likely they are to take them. This was the finding of a new study showing how copayments may be a barrier to drugs to treat pulmonary arterial hypertension.

Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022.

Deepak Bhatt, MD, MPH, details long-term outcomes from the SYMPLICITY HTN-3 trial, which show a lasting impact on patients with uncontrolled hypertension. 

A new analysis of more than 137,000 patients found that the early months of the pandemic were associated with some concerning trends for hypertension patients.